Introgen to Present ADVEXIN Phase 3 Study Results at Cancer Clinical Trials and Personalized Medicine Conference

News   Jul 21, 2008

 
Introgen to Present ADVEXIN Phase 3 Study Results at Cancer Clinical Trials and Personalized Medicine Conference
 
 
 

RELATED ARTICLES

Sartorius Stedim Biotech and Siemens Sign Automation Agreement

News

Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.

READ MORE

Algorithm Helps Diagnose Zika Using Biomarkers

News

A platform that can diagnose several diseases with a high degree of precision using metabolic markers found in patients’ blood has been developed by scientists at the University of Campinas (UNICAMP) in Brazil.

READ MORE

Retrained Enzyme is Biocatalysis Milestone

News

TU Graz researchers managed for the first time ever to ‘retrain’ an enzyme to build ring-shaped molecular structures instead of performing its natural task of reducing double bonds. The work was published in Angewandte Chemie, and is relevant for the production of pharmaceuticals and plant protection products.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE
 

We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy